City

Cairo (1)

Land O' Lakes (1)

Shanghai Shi (1)

Condition

Pharmacogenomic (3)

Age-Related Macular Degeneration (1)

Conbercept (1)

Pathological Myopia (1)

Pharmacokinetics (1)

Polypoidal Choroidal Vasculopathy (1)

Overall Status

Unknown status (2)

Not yet recruiting (1)

Sign in for free

Phase

phase 3 (1)

Sponsor

Ain Shams University (1)

Data Collection Analysis Business Management (1)

Xun Xu (1)

Collaborator

Air Force Military Medical University, China (1)

PAS Research Services (1)

Peking University (1)

Tianjin Medical University (1)

Zhongshan Ophthalmic Center, Sun Yat-sen University (1)

Intervention

empagliflozin 10 milligram (1)

intravitreal injection of conbercept (1)

pharmacogenomic (1)

Study Documents

Intervention Type

drug (2)

genetic (1)

Funder Type

Other (3)

Study Type

Observational (2)

Interventional (1)

pharmacogenomic

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Pharmacogenomic, Pharmacokinetics Trial in Cairo (Empagliflozin 10 milligram)

Not yet recruiting

Pharmacogenomic
Pharmacokinetics

Empagliflozin 10 milligram

Cairo, Egypt

Faculty of Pharmacy

Feb 5, 2022

Affect Patients' Plan of Care and Changes in Medication

Unknown status

Pharmacogenomic

pharmacogenomic

Land O' Lakes, Florida

DCABM

Jan 22, 2019

Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases

Unknown status

Age-Related Macular Degeneration
+4 more

Intravitreal injection of conbercept

Shanghai Shi, Shanghai, China

Shanghai General Hospital, Shanghai Jiao Tong University School

Apr 20, 2017